Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02066324 · ClinicalTrials.gov registry record
Urine Sample Collection From FOP Patients
A clinical trial, sponsored by Novartis Pharmaceuticals.
- Completed
- Registry status
- 25
- Enrollment target
NCT02066324: Completed study, sponsored by Novartis Pharmaceuticals.
NCT02066324 is a clinical trial that has completed, run by Novartis Pharmaceuticals. The registered enrollment target is 25 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02066324 has completed, sponsored by Novartis Pharmaceuticals.
- COMPLETED
- Registry status
- 25 participants
- Enrollment target
Study Summary
The purpose of this study is to collect urine samples from patients with fibrodysplasia ossificans progressiva (FOP) for the assessment of biomarkers related to disease, disease progression and for prediction of flare-ups of the disease. Disease related biomarkers in these patients are currently unknown. This study aims to support the development of novel therapy/ies for this disease.
Primary Outcome
The objective of this study is to collect urine samples from patients with FOP over a time period covering ideally quiescent disease status and progression through a flare-up for biomarker analysis
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 25 participants |
| Start Date | 2013-11 |
| Est. Completion | 2014-08 |
What the finished NCT02066324 record still lists
NCT02066324 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 25 participants, a relatively small participant target.
The record links to 0 conditions, and to 0 interventions.
NCT02066324 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT02066324 about?
NCT02066324 is a clinical study titled "Urine Sample Collection From FOP Patients". The purpose of this study is to collect urine samples from patients with fibrodysplasia ossificans progressiva (FOP) for the assessment of biomarkers related to disease, disease progression and for prediction of flare-ups of the disease. Disease related biomarkers in these patients are currently unk...
What is the current status of trial NCT02066324?
This trial is currently completed. The enrollment target is 25 participants. The study started on 2013-11. Estimated completion is 2014-08.
Who is sponsoring clinical trial NCT02066324?
This trial is sponsored by Novartis Pharmaceuticals, which has 1,375 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01166854 · 25 participants
Characterization of Familial Myopathy and Paget Disease of Bone
- NCT01913106 · 25 participants · Phase 1
HSV-tk + Valacyclovir Therapy in Combination With Brachytherapy for Recurrent Prostate Cancer
- NCT02138669 · 25 participants · NA
Intacs Prescription Inserts for Keratoconus Patients
- NCT02174549 · 25 participants · Phase 1
Dose-defining Study of Tirapazamine Combined With Embolization in Liver Cancer
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia